Skip to main content

Table 1 Dose escalation schedule

From: Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors

Dose level

Nb of infusion per patients

Dose per infusion

Nb of patients included

Total of infusions delivered

1

5

600 μg/m2

3

15

2

10

600 μg/m2

3

30

3

15

600 μg/m2

3

36

4

5

800 μg/m2

3

15

5

10

800 μg/m2

3

17

6

15

800 μg/m2

0

0

7

5

1000 μg/m2

0

0

8

10

1000 μg/m2

2

25

9

15

1000 μg/m2

0

0

  1. Suppression of dose level 6 and 7 after amendment of the protocol.